Fortrea and SCTbio Announce Strategic Collaboration to Accelerate Cell and Gene Therapy Development

Reuters12-04
Fortrea and SCTbio Announce Strategic Collaboration to Accelerate Cell and Gene Therapy Development

Fortrea Holdings Inc. has announced a strategic collaboration with SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products. The partnership aims to accelerate the development and delivery of cell and gene therapies by harmonizing clinical trial logistics with manufacturing readiness. By combining Fortrea's global clinical development expertise with SCTbio's manufacturing and release capabilities, the collaboration seeks to streamline planning, reduce risks, and expedite the path from early-stage development to commercialization for advanced therapies. This joint effort is designed to set a new standard for operational excellence in the field of cell and gene therapy development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596607-en) on December 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment